Cancer is one of the foremost health problems worldwide and is among the leading causes
of death in the United States. Gastrointestinal tract cancers account for almost one third of …

Summary Background Treatment of dysplastic Barrett's oesophagus prevents progression to
adenocarcinoma; however, the optimal diagnostic strategy for Barrett's oesophagus is …

Abstract Purpose of Review Esophageal cancer is a leading cause of global cancer-related
mortality. Here, we discuss the major endoscopic treatment modalities for management of …

Barrett's esophagus (BE) is defined by the replacement of the normal squamous epithelium
of the distal esophagus with metaplastic intestinal-type columnar epithelium. 1-3 BE is an …

Background Outcome data comparing endoscopic eradication therapy (EET) and
esophagectomy are limited in patients with early esophageal cancer (EC). Objective To …

Background Conflicting data exist with regard to recurrence rates of intestinal metaplasia
(IM) and dysplasia after achieving complete eradication of intestinal metaplasia (CE-IM) in …

Society for Gastrointestinal Endoscopy (ASGE)/American College of Gastroenterology
(ACG) Task Force on Quality in Endoscopy documents (27–29) provide excellent direction …

Esophageal carcinoma is a highly lethal cancer associated with high morbidity and mortality.
Esophageal squamous cell carcinoma and esophageal adenocarcinoma are the two distinct …

Background Endoscopic therapy is the preferred approach for the management of Barrett's
esophagus (BE) patients with high-grade dysplasia (HGD) and intramucosal carcinoma …

Background Esophageal adenocarcinoma has a very poor prognosis unless detected early.
The Cytosponge-trefoil factor 3 (TFF3) is a non-endoscopic test for Barrett esophagus, a …